Download link:
.
.
==>
.
privileged structures in drug discovery medicinal chemistry and synthesis by larry yet pdf
.
<==
.
.
Privileged structures in drug discovery, medicinal chemistry, and synthesis refer to molecular frameworks that have been identified as important and highly versatile in the development of bioactive compounds. These structures possess unique properties that make them particularly attractive for the design and optimization of new drugs. They are considered privileged because they have been found to interact with multiple biological targets, exhibit potent pharmacological activities, and show a high degree of structural diversity. The concept of privileged structures was first introduced by Larry Yet in the 1990s, and it has since become a valuable tool in drug discovery and development. By exploiting these structurally privileged scaffolds, medicinal chemists can streamline the process of identifying lead compounds, optimizing their properties, and ultimately developing novel therapeutic agents with improved efficacy and safety profiles. Examples of privileged structures include benzodiazepines, beta-lactams, and quinolines, among others. These scaffolds have been extensively studied and modified to generate libraries of analogs with enhanced biological activities. By leveraging the inherent properties of privileged structures, researchers can accelerate the discovery of new drug candidates and improve the success rate of drug development programs. Overall, privileged structures play a crucial role in modern drug discovery efforts, offering a strategic approach to the design and optimization of bioactive compounds. By focusing on these highly versatile molecular frameworks, researchers can expedite the development of new drugs and address unmet medical needs more effectively.